Loading...
•
Dec 31, 2021
Scorpius Holdings Q4 2021 Earnings Report
Provided strategic, financial, and operational updates for the year ended December 31, 2021.
Key Takeaways
Heat Biologics, Inc. provided strategic, financial, and operational updates for the year ended December 31, 2021. The company highlighted the progress of its clinical programs, including HS-110 for non-small cell lung cancer and PTX-35 for solid tumors, as well as its biomanufacturing capabilities and biodefense initiatives.
Presented favorable survival data of HS-110 in combination with checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC).
Announced additional dose levels for Phase 1 clinical trial evaluating the safety of PTX-35 monotherapy in patients with solid tumors.
Broke ground on a new biomanufacturing facility in San Antonio, Texas, through Scorpion Biological Services.
Announced a definitive merger agreement to acquire Elusys Therapeutics, a commercial-stage biodefense company.